Download PDF
Thromb Haemost 1990; 63(01): 054-059
DOI: 10.1055/s-0038-1645686
Original Article
Schattauer GmbH Stuttgart

Fibrin Affinity and Clearance of t-PA Deletion and Substitution Analogues

M Johannessen
*   NOVO Research Institute, Bagsvaerd, Denmark, USA
,
V Diness
*   NOVO Research Institute, Bagsvaerd, Denmark, USA
,
K Pingel
*   NOVO Research Institute, Bagsvaerd, Denmark, USA
,
L C Petersen
*   NOVO Research Institute, Bagsvaerd, Denmark, USA
,
D Rao
**   ZymoGenetics, Seattle, WA, USA
,
P Lioubin
**   ZymoGenetics, Seattle, WA, USA
,
P O’Hara
**   ZymoGenetics, Seattle, WA, USA
,
E Mulvihill
**   ZymoGenetics, Seattle, WA, USA
› Author Affiliations
Further Information

Publication History

Received 06 June 1989

Accepted after revision 12 September 1989

Publication Date:
02 July 2018 (online)

  PDF Download  Permissions and Reprints

Summary

To investigate structure-function relationships in tissue-type plasminogen activator (t-PA) we deleted the following domains in the heavy chain: a) The epidermal growth factor domain (t-PA del. G), b) the finger domain, and the epidermal growth factor domain (t-PA del. FG), and c) the finger, the epidermal growth factor and Kr-ingle 1 (1-PA del, FGK1). To study specificly the function of the growth factor domain we made two substitutions of d) 8 amino acids (consensus sequence) in the growth factor domain (t-PA G-CS) and c) the whole domain with factor IX growth factui doniuin (t-PA G-IX). Finally, f) an analogue with substitution in the finger domain (fibronectin consensus sequence) was constructed (t-PA F-CS).

A reduced fibrin binding of all the analogues was found. The fibrin stimulated activity of all analogues was also reduced and correlated to the fibrin binding. In contrast, the activity of the analogues in the clot lysis assay and the plate assay were only slightly reduced as compared to authentic t-PA. This suggested that at high fibrin concentrations the decreased fibrin affinity was less ciitical for obtaining a high fibrinolytic activity.

All analogues had a prolonged half-life in vivo as compared to authentic t-PA. The assumption of clearance mechanism involving mainly the growth factor region (or Kringlc 1) was not challenged by the observation of a prolonged half-life for the substitution analogue t-PA F-CS.

Our results indicate that a high affinity for fibrin and rapid elimination in vivo of t-PA require a nearly intact conformation of the N-terminal part of the molecule.

Keywords

Tissue-type plasminogen activator - Deletion analogues - Substitution analogues - Fibrin binding - Clearance - Fibrin stimulation - Clot lysis activity
 

  • References

  • 1 Bachmann F. Plasminogen activators. In: Haemostasis and Thrombosis: Basic Principles and Clinical Practice Colman R, Hirsh J, Marder V, Salzman E. (eds). Lippincott Company; 1987. 2 318-339
  • 2 Higgins DL, Vehar GA. Interaction of one-chain and two-chain tissue plasminogen activator with intact and plasmin-degraded fibrin. Biochemistry 1987; 26: 7786-7791
    CrossrefPubMedGoogle Scholar
  • 3 Tate KM, Higgins DL, Holmes WE, Winkler ME, Heyneker HL, Vehar GA. Functional role of proteolytic cleavage at arginine-275 of human tissue plasminogen activator as assessed by site-directed mutagenesis Biochemistry 1987; 26: 338-343
    CrossrefPubMed
  • 4 Zoller MJ, Smith M. Oligonucleotide-directed mutagenesis: a simple method using two oligonucleotide primers and a single-stranded DNA template. DNA 1984; 3 (06) 479-488
    CrossrefPubMedGoogle Scholar
  • 5 Graham FL, van der Eb AJ. A new technique for the assay of infectivity of human adenovirus 5 DNA. Virology 1973; 52: 456-462
    CrossrefPubMedGoogle Scholar
  • 6 Bradshaw HD, Parson WW, Sheffer M, Lioubin PJ, Mulvihill ER, Gordon MP. Design, construction, and use of an clcctroporator for plant protoplasts and animal cells. Analyt. Biochemistry 1987; 166: 342-348
    PubMedGoogle Scholar
  • 7 McCracken AA, Brown JL. A filter immunoassay lor detection ol protein secreting cell colonies. Biotechniques March/April 1984; 82-87
    PubMedGoogle Scholar
  • 8 Selmer J, Brender J, Suensen E, Thorsen S. Characterization of monochain tissue type plasminogen activator (t-PA) purified by immunoadsorption to a monoclonal antibody. In: Clinical Aspects of Fibrinolysis and Thrombolysis Jespersen J, Kluft C, Korsgaard O. (eds). South Jutland University Press; Esbjerg: 1983: 43-46
  • 9 Petersen LC, Johannessen M, Foster D, Kumar A, Mulvihill E. The effect of polymerized fibrin on the catalytic activities of one-chain tissue type plasminogen activator as revealed by an analogue resistant to plasmin elenvnge. Biochim Biophys Acta 1988; 952: 245-254
    CrossrefPubMedGoogle Scholar
  • 10 Astrup T, Kok P. Assay and preparation of a tissue plasminogen activator. Methods Enzymol 1970; 19: 821-834
    PubMedGoogle Scholar
  • 11 Brender J, Selmer J. ELISA of human tissue type plasminogen activator applying monoclonal antibody. In: Clinical Aspects of Fibrinolysis and Thrombolysis Jespersen J, Kluft C, Korsgaard U. (eds). South Jutland University Press; Esbjerg: 1983: 83-84
  • 12 Philo PD, Gaffney PJ. Plasmin potency estimates: influences of the substrate used in assay. Thromb Hacmostas 1981; 45 (02) 107-109
    PubMedGoogle Scholar
  • 13 Gaffney PJ, Templeman J, Curtis AD, Campbell PJ. The stability of tissue plasminogen activator (t-PA). Thromb Haemostas 1983; 50 (03) 650-651
    PubMedGoogle Scholar
  • 14 Finney. Statistical Method in Biological Assay. Griffin London: 1978
    Google Scholar
  • 15 Smith PK, Krohn RI, Hermanson GT, Mallia AK, Gartner FH, Provenzano MD, Fujimoto EK, Goeke NM, Olson BJ, Klenk DC. Measurement of protein using Bicinchoninic acid. Anal Biochem 1985; 150: 76-85
    CrossrefPubMedGoogle Scholar
  • 16 Petersen LC, Handest P, Brender J, Selmer J, JØrgensen M, Thorsen S. A Sensitive Solid-Phase Immunosorbent Assay for Tissue-Type Plasminogen Activator Activity in Plasma Using Trinitrobenzoylated Poly-D-Lysine as a Stimulator for Plasminogen Activation. Thromb Haemostas 1987; 57 (02) 205-211
    PubMedGoogle Scholar
  • 17 Larsen GR, Henson K, Blue Y. Variants of human tissue-type plasminogen activator. J Biol Chem 1988; 263: 1023-1029
    PubMedGoogle Scholar
  • 18 Verheijen JH, Caspers MP M, Chang GT G, de Munk GA W, Pouwels PH, Enger-Valk BE. Involvement of finger domain and Kringle 2 domain of tissue-type plasminogen activator in fibrin binding and stimulation of activity by fibrin. Embo J 1986; 5 (13) 3525-3530
    PubMedGoogle Scholar
  • 19 Collen D, Stassen J, Larsen G. Pharmacokinetics and thrombolytic properties of deletion mutants of human tissue-type plasminogen activator in rabbits. Blood 1988; 71: 216-219
    PubMedGoogle Scholar
  • 20 Zonnenveld A, Veerman H, MacDonald M, Mourik J, Pannekoek H. Structure and function of human tissue-type plasminogen activator (t-PA). J Cellular Biochem 1986; 32: 169-178
    CrossrefPubMedGoogle Scholar
  • 21 Kalyan KK, Lee SG, Wilhelm J, Fu KP, Hum W, Rapaport R, Hartzell RW, Urbano C, Hung PP. Structure function analysis with tissue-type plasminogen activator. J Biol Chem 1988; 263 (06) 3971-3978
    PubMedGoogle Scholar
  • 22 Dodd I, Nunn B, Robinson JH. Isolation, identification and pharmacokinetic properties of tissue-type plasminogen activator species: Possible localization of a clearance recognition site. Thromb Haemostas 1988; 59 (03) 523-528
    PubMedGoogle Scholar
  • 23 Fu KP, Lee S, Hum WT, Kalyan N, Rapaport R, Hetzel R, Hung P. Disposition of a novel recombinant tissue plasminogen activator, delta 2-89 t-PA, in mice. Thromb Res 1988; 50: 33-41
    PubMedGoogle Scholar
  • 24 Rijken DC, Emeis JJ. Clearance of the heavy and light polypeptide chains of human tissue-type plasminogen activator in rats. Biochem J 1986; 238: 643-646
    CrossrefPubMedGoogle Scholar